clinical_trials
Trial Results Show 'Something We Have Not Seen for Years' in Osteosarcoma
Confidence86·multiple reportsImportance88NP-EVT-20261027-2E2CA22
(MedPage Today) -- The investigational antibody-drug conjugate (ADC) risvutatug rezetecan (Ris-Rez) significantly improved progression-free survival (PFS) in patients with relapsed or refractory osteosarcoma, the phase III ARTEMIS-011 trial from...
Read the original at the primary source
Trial Results Show 'Something We Have Not Seen for Years' in Osteosarcoma
10/27/2026, 4:53:04 PM
Also on the network: airlinesairports · farmerspulse · foodpulse · indianhealthpulse · indias · keralahealth · naturepulse · travelerpulse
Discussion
ChatsPulse · 0 threads
No discussion yet. Sign in and start the first thread —